Immunovant ramps IMVT‑1402 trials, burns cash but has $599M runway to 2027 GD readout

Immunovant, Inc. (NASDAQ: IMVT) - Quick internal update

What's happening inside: management is aggressively advancing its next‑generation FcRn candidate IMVT‑1402 across multiple potentially registrational programs while maintaining batoclimab development with partner HanAll. The company is burning cash to scale trials and headcount but reports a substantial cash balance and says current funds should carry through the Graves' disease (GD) readout expected in 2027.

Key facts & figures (from the Form 10‑Q, as reported)

* Cash and cash equivalents: $598,912 (in thousands) - cash declined from $713,971 at March 31, 2025.

* Total assets: $661,440 (in thousands); Total liabilities: $52,900 (in thousands); Total stockholders' equity: $608,540 (in thousands).

* Cash used in operating activities (3 months ended June 30, 2025): $(117,411) (in thousands).

* Net loss (3 months ended June 30, 2025): $(120,613) (in thousands) vs. $(87,150) in prior-year period - change: $(33,463) (in thousands).

* Loss before income taxes: $(119,700) (in thousands); Provision for income taxes: $913 (in thousands).

* Net loss per share - basic & diluted: $(0.71) for Q1 FY2026 vs. $(0.60) prior year; Weighted‑average common shares outstanding: 170,872,994.

* Operating expenses - R&D: $101,200 (in thousands) vs. $75,473 prior year; G&A: $26,024 (in thousands) vs. $18,808 prior year; Total operating expenses: $127,224 (in thousands).

* Stock‑based compensation: $18,395 (in thousands) for the quarter; total unrecognized compensation: $61.3M (options) + $79.6M (RSUs).

* Shares outstanding (June 30, 2025): 171,069,176; Series A preferred outstanding: 10,000 (held by Roivant Sciences Ltd.).

* Contractual commitments: minimum Samsung purchase obligation approx. $43.1 million remaining; HanAll agreement milestone pool - aggregate maximum $420.0 million (after aggregate $32.5 million paid as of June 30, 2025).

Operational highlights

* IMVT‑1402: six IND clearances and initiated studies across multiple indications (GD, D2T RA, MG, CIDP, Sjögren's, CLE); management cites potential "best‑in‑class" profile and expects ~80% IgG reductions at 600 mg dose.

* Batoclimab: ongoing Phase 3 TED program - top‑line results expected H2 2025; Phase 2 GD proof‑of‑concept continuing with data planned for ATA meeting (September 2025).

* Management guidance: existing cash "sufficient to fund announced indications to date through our GD readout expected in 2027."

Positive aspects (income statement & business)

* Strong liquidity runway on reported figures - $598,912 (in thousands) cash and equivalents provides runway toward major catalysts (management guidance to GD 2027).

* Increased investment into R&D is deliberate and tied to multiple potentially registrational trials - spending is supporting clear clinical development progress and near‑term catalysts.

* Non‑cash stock‑based compensation (major portion of G&A/R&D increases) cushions immediate cash impact; continued access to equity markets and ATM facility exists.

Negative aspects (income statement & risks)

* Rapidly rising burn: net loss widened to $(120,613) (in thousands) and operating cash burn was $(117,411) (in thousands) for the quarter - R&D up $25.7M YoY and G&A up $7.2M YoY.

* No revenues: the company remains pre‑revenue and dependent on financing to fund development; accumulated deficit is $(1,360,136) (in thousands).

* Financing risk and future cash needs: contingent milestone exposure (HanAll) and Samsung purchase commitments add potential near‑term cash demands; company states need to raise additional capital to fully implement plan.

* Net interest income pressure: interest income decreased to offset lower yield environment, reducing non‑operating offsets to losses.

Near‑term catalysts & watchlist

* Batoclimab Phase 3 TED top‑line - expected H2 2025 (material to partnership decisions).

* IMVT‑1402 registrational trials - GD, MG, CIDP, D2T RA, SjD timelines: readouts staggered (GD readout expected 2027; other indications into 2026-2028).

* Cash‑management moves - potential equity raises, partnerships, or use of ATM program if burn continues to outpace available cash.

Bottom line

Immunovant is funding an accelerated clinical build for IMVT‑1402 while maintaining batoclimab programs. Financials show deliberate heavy R&D spend and increasing G&A driving a wider quarterly loss and higher cash burn, but the balance sheet still carries material cash (~$598.9M) and management says it's sufficient to reach the next major GD readout in 2027. Key risks remain: zero revenue, significant additional capital likely required to complete multiple registrational programs, contractual commitments (Samsung) and milestone exposure under HanAll. Investors should monitor upcoming trial readouts and any financing activity closely.